Immune Checkpoint Blockade: The Hope for Immunotherapy as a Treatment of Lung Cancer?

Por Brahmer, Julie R.
Publicado no Semin Oncol (2013)

Antiangiogenic Agents in Combination with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer

Por Ulahannan, Susanna V, Brahmer, Julie R
Publicado em 2011

Immune Checkpoint Inhibitors: Making Immunotherapy a Reality for the Treatment of Lung Cancer

Por Brahmer, Julie R., Pardoll, Drew M.
Publicado no Cancer Immunol Res (2013)

Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer

Por Drake, Charles G., Lipson, Evan J., Brahmer, Julie R.
Publicado em 2013

New Strategies in Lung Cancer: Epigenetic Therapy for Non–Small Cell Lung Cancer

Por Forde, Patrick M., Brahmer, Julie R., Kelly, Ronan J.
Publicado no Clin Cancer Res (2014)

Oligometastatic Adenocarcinoma of the Lung: A Therapeutic Opportunity for Long-Term Survival

Por Yarchoan, Mark, Lim, Michael, Brahmer, Julie R, Ettinger, David
Publicado no Cureus (2015)

Regulatory T cells—an important target for cancer immunotherapy

Por Drake, Charles G., Lipson, Evan J., Brahmer, Julie R.
Publicado no Nat Rev Clin Oncol (2014)

Harnessing the power of the immune system via blockade of PD-1 and PD-L1: a promising new anticancer strategy

Por Reiss, Kim A, Forde, Patrick M, Brahmer, Julie R
Publicado no Immunotherapy (2014)

Nivolumab in NSCLC: latest evidence and clinical potential

Por Sundar, Raghav, Cho, Byoung-Chul, Brahmer, Julie R., Soo, Ross A.
Publicado no Ther Adv Med Oncol (2015)

Emerging Treatments for Choroidal Metastases

Por Chen, Connie J., McCoy, Allison N., Brahmer, Julie, Handa, James T.
Publicado no Surv Ophthalmol (2011)

What Lies Within: Novel Strategies in Immunotherapy for Non-Small Cell Lung Cancer

Por Forde, Patrick M., Reiss, Kim A., Zeidan, Amer M., Brahmer, Julie R.
Publicado em 2013

Immunotherapy in the treatment of non-small cell lung cancer

Por Sundar, Raghav, Soong, Richie, Cho, Byoung-Chul, Brahmer, Julie R., Soo, Ross A.
Publicado no Lung Cancer (2014)

Clinical Course of Advanced Non–Small-Cell Lung Cancer Patients Experiencing Hypertension During Treatment With Bevacizumab in Combination With Carboplatin and Paclitaxel on ECOG 4...

Por Dahlberg, Suzanne E., Sandler, Alan B., Brahmer, Julie R., Schiller, Joan H., Johnson, David H.
Publicado em 2010

Prognostic Models to Predict Survival in Non-Small Cell Lung Cancer Patients Treated with First-Line Paclitaxel and Carboplatin with or without Bevacizumab

Por Hoang, Tien, Dahlberg, Suzanne E., Sandler, Alan B., Brahmer, Julie R., Schiller, Joan H., Johnson, David H.
Publicado em 2012

Genetic and Proteomic Features Associated with Survival after Treatment with Erlotinib in First-Line Therapy of Non-small Cell Lung Cancer in Eastern Cooperative Oncology Group 350...

Por Amann, Joseph M., Lee, Ju-Whei, Roder, Heinrich, Brahmer, Julie, Gonzalez, Adriana, Schiller, Joan H., Carbone, David P.
Publicado em 2010

Sex Differences in Outcome with Bevacizumab Therapy: Analysis of Patients with Advanced-Stage Non-Small-Cell Lung Cancer Treated with or without Bevacizumab in Combination with Pac...

Por Brahmer, Julie R., Dahlberg, Suzanne E., Gray, Robert J., Schiller, Joan H., Perry, Michael C., Sandler, Alan, Johnson, David H.
Publicado em 2011

Retrospective Evaluation of the Clinical and Radiographic Risk Factors Associated With Severe Pulmonary Hemorrhage in First-Line Advanced, Unresectable Non–Small-Cell Lung Cancer T...

Por Sandler, Alan B., Schiller, Joan H., Gray, Robert, Dimery, Isaiah, Brahmer, Julie, Samant, Meghna, Wang, Lisa I., Johnson, David H.
Publicado em 2009

Body Mass Index and its Association with Clinical Outcomes for Advanced Non-Small Cell Lung Cancer Patients Enrolled on Eastern Cooperative Oncology Group Clinical Trials

Por Dahlberg, Suzanne E., Schiller, Joan H., Bonomi, Philip B., Sandler, Alan B., Brahmer, Julie R., Ramalingam, Suresh S., Johnson, David H.
Publicado em 2013

Development of MEDI4736, an anti-programmed cell death ligand 1 (PD-L1) antibody, as monotherapy or in combination with other therapies in the treatment of non-small cell lung canc...

Por Brahmer, Julie, Balmanoukian, Ani, Goldberg, Sarah, Ou, Sai-Hong, Blake-Haskins, Andrew, Karakunnel, Joyson, Stockman, Paul, Rizvi, Naiyer, Antonia, Scott
Publicado no J Immunother Cancer (2014)

An open label randomized Phase III trial of nivolumab or nivolumab plus ipilimumab vs platinum doublet chemotherapy (PT-DC) in patients with chemotherapy-naïve stage IV or recurren...

Por Hellmann, Matthew, Ramalingam, Suresh, Reck, Martin, O'Byrne, Ken, Paz-Ares, Luis, Harbison, Christopher T, Bhagavatheeswaran, Prabhu, Nathan, Faith, Brahmer, Julie
Publicado no J Immunother Cancer (2015)